TM Editors Note: This article discusses one or more penny stocks and/or microcaps. Such stocks are readily manipulated; do your own careful due diligence.

Algernon Pharmaceuticals Inc. - Symbols AGN (OTCQB: AGNPF) and AGN.WT trading on the Canadian Stock Exchange (CSE)

The common shares have gone from C$.04 to C$.54 since November 2019 - UP 1250%
The stock warrantshave gone from C$.01 to C$.42 since November 2019 - UP 4,100%

Here is the story.....

Algernon Pharmaceuticals is a clinical-stage drug development company focused on the areas of non–alcoholic steatohepatitis (NASH), chronic kidney disease (CKD), inflammatory bowel disease (IBD), and idiopathic pulmonary fibrosis (IPF).

On November 1, 2019, they announced the closing of $2.07 million prospectus offering of units which included the stock warrants.

Each Unit is comprised of one common share in the capital of the Company (a “Unit Share”) and one common share purchase warrant (a “Warrant”). Each Warrant will entitle the holder thereof to acquire, subject to adjustment in certain circumstances, one common share in the capital of the Company (each, a “Warrant Share”) at the price of $0.12 per Warrant Share until May 1, 2022 (the “Expiry Date”), subject to acceleration of the Expiry Date as described below.

If at any time prior to the Expiry Date, the volume-weighted average trading price of the common shares of the Company (the “Common Shares”) on the Canadian Securities Exchange (the “CSE”), or other principal exchange on which the Common Shares are listed, is greater than $0.35 for 20 consecutive trading days, the Company may, within 15 days of the occurrence of such event, deliver a notice to the holders of Warrants accelerating the Expiry Date to the date that is 30 days following the date of such notice (the “Accelerated Exercise Period”). Concurrent with the giving of such notice, the Company will also issue a press release disclosing the Accelerated Exercise Period. Any unexercised Warrants shall automatically expire at the end of the Accelerated Exercise Period.

On March 6, 2020, the company issued the following press release:

Algernon Explores the Use of NP-120 (Ifenprodil) as a Novel Treatment for Coronavirus

This press release brought an immediate reaction in the markets and common shares almost doubled and have not looked back. Obviously this is a news-driven story as the world is focused on the Covid-19.

Most recently on April 23, 2020, the company issued the following press release:

Algernon Receives Regulatory and Ethics Approval for Phase 2 Ifenprodil COVID-19 Human Study in South Korea

(Click on image to enlarge)

(Click on image to enlarge)

Above we present the charts for both the common shares and the stock warrants as they reflect the incredible potential of investing in stock warrants as soon as possible.

Question For Investors:

Is it too late to buy the common shares or the stock warrants?

The answer obviously depends upon the view of any individual investor, but the argument can be made that the large percentage gains are behind us. However, it is still possible for interested investors to explore the volatility of this developing situation.

Investors should have access to a list of companies with stock warrants to stay on top of future opportunities.